HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hanying Liu Selected Research

cudraxanthone L

9/2021Cudraxanthone L inhibits gastric cancer by regulating the MAPK signalling and promoting FAS-mediated pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hanying Liu Research Topics

Disease

2Diabetic Retinopathy (Retinopathy, Diabetic)
03/2021 - 01/2021
1Idiopathic Pulmonary Fibrosis
01/2022
1Pulmonary Fibrosis (Fibrosing Alveolitis)
01/2022
1Stomach Neoplasms (Stomach Cancer)
09/2021
1Neoplasms (Cancer)
09/2021
1Necrosis
10/2016

Drug/Important Bio-Agent (IBA)

1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2022
1cudraxanthone LIBA
09/2021
1Proteins (Proteins, Gene)FDA Link
09/2021
1MicroRNAs (MicroRNA)IBA
03/2021
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021
1Panax notoginseng extractIBA
01/2021
1Complement System Proteins (Complement)IBA
01/2021
1Therapeutic UsesIBA
01/2021
1Messenger RNA (mRNA)IBA
10/2016
1Nitric Oxide (Nitrogen Monoxide)FDA Link
10/2016
1Interleukin-6 (Interleukin 6)IBA
10/2016